Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RISPERDAL vs BRISDELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Risperidone is a benzisoxazole atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. It also blocks alpha1-adrenergic, alpha2-adrenergic, and histamine H1 receptors.
Selective serotonin reuptake inhibitor (SSRI); paroxetine is the active ingredient. Enhances serotonergic activity by blocking serotonin reuptake into presynaptic neurons, augmenting serotonin levels in the synaptic cleft.
Schizophrenia (FDA-approved),Bipolar I disorder (acute manic or mixed episodes) (FDA-approved),Irritability associated with autistic disorder (FDA-approved),Treatment-resistant depression (adjunctive to antidepressants) (off-label),Tourette's disorder (off-label),Obsessive-compulsive disorder (adjunctive) (off-label),Post-traumatic stress disorder (off-label),Delirium (off-label)
FDA-approved: Treatment of moderate to severe vasomotor symptoms (hot flashes) associated with menopause.,Off-label: Management of depression, anxiety disorders, obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder, premenstrual dysphoric disorder.
2-8 mg orally once daily or divided twice daily; maximum 16 mg/day
8 mg orally once daily, taken at bedtime.
20 hours (parent drug), 23 hours (active metabolite 9-hydroxyrisperidone). Steady state reached in 5-6 days. Extended in elderly and hepatic/renal impairment.
Terminal elimination half-life is approximately 9-11 hours for paroxetine (the active ingredient in Brisdelle). This supports once-daily dosing; steady-state is achieved within 7-14 days.
Risperidone is extensively metabolized by cytochrome P450 2D6 (CYP2D6) to its active metabolite, 9-hydroxyrisperidone (paliperidone). A minor pathway involves CYP3A4 and CYP3A5. The metabolite is further metabolized via N-dealkylation and oxidative pathways.
Extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2D6. Metabolites are glucuronidated and excreted renally.
Renal: 70% (30% as unchanged drug, 40% as metabolites), Fecal/Biliary: 14%
Primarily renal excretion as metabolites; approximately 60% of a radiolabeled dose is recovered in urine and 30% in feces over 10 days. Less than 1% excreted unchanged.
90% (albumin and alpha-1-acid glycoprotein). Active metabolite 77% bound.
Approximately 95% bound to plasma proteins, primarily to albumin and alpha-1 acid glycoprotein.
1-2 L/kg. Large Vd indicates extensive tissue distribution and penetration into CNS.
Volume of distribution is about 3-28 L/kg (mean ~13 L/kg), indicating extensive tissue distribution.
Oral: 70% (with extensive first-pass metabolism). IM: 100% for immediate-release. Long-acting IM: fraction absorbed over depot injection.
Oral bioavailability is approximately 50-100% due to extensive first-pass metabolism; absolute bioavailability is about 50% for the immediate-release formulation.
Cr Cl <30 m L/min: initial 0.5 mg twice daily, increase by 0.5 mg increments; max 3 mg/day
No dose adjustment required for mild-to-moderate renal impairment (Cr Cl ≥ 30 m L/min). For severe renal impairment (Cr Cl < 30 m L/min) or end-stage renal disease, not recommended due to lack of data.
Child-Pugh class A or B: initial 0.5 mg twice daily, increase by 0.5 mg increments; max 3 mg/day; Child-Pugh C: not studied
Mild hepatic impairment (Child-Pugh A): no adjustment. Moderate hepatic impairment (Child-Pugh B): maximum dose 4 mg orally once daily. Severe hepatic impairment (Child-Pugh C): contraindicated.
13-17 yr: 0.5 mg once daily, titrate by 0.5-1 mg/day at ≥24 hr intervals; target 3 mg/day; max 6 mg/day. 10-12 yr: 0.5 mg once daily, titrate by 0.5 mg/day; target 1-2.5 mg/day; max 3 mg/day
Not approved for use in pediatric patients; safety and efficacy not established.
Initial 0.5 mg twice daily; increase by 0.5 mg increments; max 3 mg/day; monitor for orthostatic hypotension and sedation
For patients >65 years, start with 4 mg orally once daily at bedtime; may increase to 8 mg once daily based on response and tolerability. Monitor closely for sedation and falls.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Risperidone is not approved for the treatment of dementia-related psychosis.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Increased mortality in elderly patients with dementia-related psychosis,Cerebrovascular adverse events (e.g., stroke, transient ischemic attack) in elderly with dementia,Neuroleptic malignant syndrome (NMS),Tardive dyskinesia,Hyperglycemia and diabetes mellitus,Weight gain,Dyslipidemia,Orthostatic hypotension and syncope,Seizures,Leukopenia, neutropenia, and agranulocytosis,QT interval prolongation,Hyperprolactinemia,Body temperature dysregulation,Dysphagia,Priapism,Thrombotic thrombocytopenic purpura (TTP)
Suicidality risk in young adults,Serotonin syndrome with concurrent serotonergic drugs,Bone fractures risk,Sexual dysfunction,Abnormal bleeding risk,Angle-closure glaucoma risk,Hyponatremia in elderly or volume-depleted patients,Discontinuation syndrome upon abrupt withdrawal,Pregnancy: Potential harm to neonates (persistent pulmonary hypertension, serotonin syndrome),Lactation: Excreted in breast milk
Hypersensitivity to risperidone, paliperidone, or any component of the formulation
Concomitant use with MAOIs (or within 14 days of MAOI discontinuation),Concomitant use with thioridazine,Concomitant use with pimozide,Hypersensitivity to paroxetine or any component,Pregnancy (especially third trimester) due to risk of neonatal complications
Grapefruit juice may increase risperidone levels; avoid concurrent use. Risperidone can be taken with or without food. High-fat meals do not affect absorption. Weight gain is common; encourage heart-healthy diet. Alcohol may exacerbate CNS depression and orthostatic hypotension; advise avoidance.
Avoid alcohol due to additive central nervous system depression. No specific food interactions; take without regard to meals.
First trimester: Limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: Risk of extrapyramidal symptoms and/or withdrawal symptoms in neonates if exposed during third trimester. Overall, not considered a major teratogen.
Pregnancy Category C. In animal studies, paroxetine (active ingredient of Brisdelle) has been associated with increased fetal malformations (including cardiovascular) at doses greater than human therapeutic doses. In humans, retrospective studies suggest a small increased risk of congenital heart defects (primarily ventricular septal defects) with first-trimester exposure. Third-trimester exposure may increase risk for persistent pulmonary hypertension of the newborn (PPHN) and neonatal withdrawal syndrome (respiratory distress, feeding difficulties, jitteriness).
Risperidone and its active metabolite 9-hydroxyrisperidone are excreted in breast milk. Milk-to-plasma ratio (M/P) approximately 0.42-0.44. Relative infant dose is about 4-9% of maternal weight-adjusted dose. Monitor infant for sedation, poor feeding, and extrapyramidal symptoms. Consider benefits of breastfeeding vs. risk.
Paroxetine is excreted into breast milk in low concentrations. The milk-to-plasma ratio (M/P) is approximately 0.5-0.7. Estimated infant dose is 1-2% of maternal weight-adjusted dose. No adverse effects have been consistently reported in breastfed infants, but caution is advised due to potential for serotonin-related effects. Benefits versus risks should be assessed.
Increased plasma volume and hepatic metabolism may lower risperidone concentrations, especially in second and third trimesters. Dose adjustments may be needed; monitor clinical response and consider therapeutic drug monitoring. No standard dose adjustment recommendation; titrate to effect.
No specific dose adjustment is recommended solely due to pregnancy; however, pharmacokinetic changes in pregnancy (increased volume of distribution, hepatic metabolism) may lead to decreased drug levels. Clinical monitoring and dose titration based on therapeutic response and tolerability are advised. Avoid abrupt discontinuation to prevent withdrawal effects.
Risperdal (risperidone) is a second-generation antipsychotic with high affinity for D2 and 5-HT2A receptors. Monitor for orthostatic hypotension during dose titration, especially in elderly. QT prolongation risk is dose-dependent; avoid with hypokalemia, hypomagnesemia, or concomitant QT-prolonging drugs. Therapeutic response for psychosis may take 2-4 weeks. For agitation, consider sublingual or IM formulations. Extrapyramidal symptoms are dose-related; more common at doses >6 mg/day. Prolactin elevation is more pronounced than with other atypical antipsychotics; monitor for galactorrhea, gynecomastia, menstrual irregularities. Weight gain and metabolic syndrome require baseline and periodic monitoring of BMI, fasting glucose, and lipids. Risk of tardive dyskinesia with long-term use. In elderly with dementia-related psychosis, increased mortality.
BRISDELLE (paroxetine mesylate) is a selective serotonin reuptake inhibitor (SSRI) indicated for vasomotor symptoms (VMS) in menopause. It is the only non-hormonal therapy FDA-approved for moderate to severe VMS. Dosing starts at 7.5 mg once daily, typically at bedtime to minimize daytime sedation. Avoid concurrent use with MAOIs, other SSRIs/SNRIs, or strong CYP2D6 inhibitors (e.g., paroxetine itself). Monitor for serotonin syndrome, especially with triptans or linezolid. Discontinue gradually to avoid withdrawal symptoms. Note that paroxetine is pregnancy category D; use effective contraception.
Take risperidone exactly as prescribed; do not crush or chew tablets.,Avoid alcohol and grapefruit juice as they may worsen side effects.,Rise slowly from sitting or lying to prevent dizziness or fainting.,Report unusual muscle stiffness, tremors, or restlessness immediately.,Notify your doctor if you experience breast swelling, discharge, or sexual dysfunction.,Risperidone may cause drowsiness; avoid driving until you know how the drug affects you.,Do not stop abruptly; withdrawal may cause nausea, vomiting, or insomnia.,Use effective contraception if of childbearing potential; discuss pregnancy plans with your doctor.,Avoid overheating or dehydration; increased body temperature may occur.
Take BRISDELLE at bedtime to reduce daytime drowsiness.,Do not crush or chew the capsule; swallow whole.,It may take 2–4 weeks to see full benefit for hot flashes.,Avoid alcohol as it can increase sedation.,Do not stop suddenly; taper under medical guidance.,Report any suicidal thoughts, worsening depression, or unusual behavior changes.,Contact doctor if you experience severe headache, nausea, or rapid heartbeat (serotonin syndrome).,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RISPERDAL vs BRISDELLE, answered by our medical review team.
RISPERDAL is a Atypical Antipsychotic that works by Risperidone is a benzisoxazole atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. It also blocks alpha1-adrenergic, alpha2-adrenergic, and histamine H1 receptors.. BRISDELLE is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); paroxetine is the active ingredient. Enhances serotonergic activity by blocking serotonin reuptake into presynaptic neurons, augmenting serotonin levels in the synaptic cleft.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RISPERDAL and BRISDELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RISPERDAL is: 2-8 mg orally once daily or divided twice daily; maximum 16 mg/day. The standard adult dose of BRISDELLE is: 8 mg orally once daily, taken at bedtime.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RISPERDAL and BRISDELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RISPERDAL is classified as Category C. First trimester: Limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: Risk of extrapyramidal symptoms an. BRISDELLE is classified as Category C. Pregnancy Category C. In animal studies, paroxetine (active ingredient of Brisdelle) has been associated with increased fetal malformations (including cardiovascular) at doses grea. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.